{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/336345614"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Biogen Idec announced that it exercised its right to enter into an agreement with joint venture partner Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn???s disease." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "businesswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/352028105"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/336345614" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/318770504"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/336345614"] } } }
